1. Berggren KL, Tharp M, Boyer KM: Vaccine-associated “wild-type” measles. Pediatr Dermatol 22:130, 2005
2. Pediatrics, A.A.o: Rubella. In: Red Book: 2009 Report of the Committee on Infectious Diseases, edited by LK Pickering, CJ Baker, DW Kimberlin, SS Long. Elk Grove Village, IL, American Academy of Pediatrics, 2009, p. 444
3. Muller CP et al: Reducing global disease burden of measles and rubella: Report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine 25:1, 2007
4. Stalkup JR: A review of measles virus. Dermatol Clin 20:209, 2002
5. World Health Organization: Global reduction in measles mortality 2000–2008 and the risk of measles resurgence. Wkly Epidemiol Rec 49:509, 2009
6. Griffin DE, Ward BJ, Esolen LM: Pathogenesis of measles virus infection: An hypothesis for altered immune responses. J Infect Dis 170:S24, 1994
7. De Swart RL: The pathogenesis of measles revisited. Pediatr Infect Dis J 27:S84, 2008
8. Atkinson WL: Epidemiology and prevention of measles. Dermatol Clin 13:553, 1995
9. De Serres G, Gay NJ, Farrington CP: Epidemiology of transmissible diseases after elimination. Am J Epidemiol 151:1039, 2000
10. Hallsworth PG, McDonald PJ: Rapid diagnosis of viral infections with fluorescent antisera. Pathology 17:629, 1985
11. Nakayama T: Laboratory diagnosis of measles and rubella infection. Vaccine 27:3228, 2009
12. Bellini WJ, Helfand RF: The challenges and strategies for laboratory diagnosis of measles in an international setting. J Inf Dis 187:S283, 2003
13. CDC: Measles-United States, 1995. MMWR Morb Mortal Wkly Rep 45:305, 1996
14. Markowitz LE et al: Patterns of transmission in measles outbreaks in the United States, 1985–1986. N Engl J Med 320:75, 1989
15. Moussallem TM et al: Lung involvement in childhood measles: Severe immune dysfunction revealed by quantitative immunohistochemistry. Hum Pathol 38:1239, 2007
16. Vitek CR et al: Trends in importation of measles to the United States, 1986–1994. JAMA 277:1952, 1997
17. American Academy of Pediatrics Committee on Infectious Diseases: Vitamin A treatment of measles. Pediatrics 91:1014, 1993
18. Yang HM, Mao M, Wan CM: Vitamin A for treating measles in children. Cochrane Database Syst Rev 4:CD001479, 2005
19. CDC: Measles prevention. MMWR Morb Mortal Wkly Rep 38:1, 1989
20. Inamadar
AC, Patil SS, Palit A: Severe cutaneous reaction following measles immunization.
Int J Dermatol 48:873, 2009
21. Gerber JS, Offit PA: Vaccines and autism: A tale of shifting hypotheses. Clin Infect Dis 48:456, 2009
22. Davis RL, Bohlke K: Measles vaccination and inflammatory bowel disease: Controversy laid to rest? Drug Saf 24:939, 2001
23. Baird G et al: Measles vaccination and antibody response in autism spectrum disorders. Arch Dis Child 93:832, 2008
24. Schattner A: Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23:3876, 2005
25. Bernsen RMD, van der Wouden JC: Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children. Pediatr Allergy Immunol 19:544, 2008
26. CDC: Rubella. In: Red Book: 2009 Report of the Committee on Infectious Diseases, edited by LK Pickering, CJ Baker, DW Kimberlin, SS Long. Elk Grove Village, IL: American Academy of Pediatrics, 2009, p. 579
27. Louie JK et al: Re-emergence of another vaccine-preventable disease? – Two cases of rubella in older adults. J Clin Virol 46:98, 2009
28. Vander Straten MR, Tyring SK: Rubella. Dermatol Clin 20:225, 2002
29. Kimberlin DW: Rubella immunization. Pediatr Ann 26:366, 1997
30. CDC: Control and prevention of rubella: Evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR Recomm Rep 50:1, 2001
31. Abernathy E et al: Confirmation of rubella within 4 days of rash onset: Comparison of rubella virus RNA detection in oral fluid with immunoglobulin M detection in serum or oral fluid. J Clin Microbiol 47:182, 2009
32. Pool V, Chen R, Rhodes R: Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura. Pediatr Infect Dis J 16:423, 1997
33. Baykan A, Akcakus M, Deniz K: Rubella-associated hemophagocytic syndrome in an infant. J Pediatr Hematol Oncol 27:430, 2005
34. Guler E et al: Encephalitis in a child during atypical course of rubella. Infection 37:65, 2009
35. Gale EAM: Congenital rubella: Citation virus or viral cause of type 1 diabetes? Diabetologia 51:1559, 2008
36. Badilla X et al: Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis 26:830, 2007
37. Cohen BJ, Buckley MM: The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 25:151, 1988
38. Plummer FA et al: An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med 313:74, 1985
39. Anderson MJ et al: Experimental parvoviral infection in humans. J Infect Dis 152:257, 1985
40. McCarter-Spaulding D: Parvovirus B19 in pregnancy. J Obstet Gynecol Neonatal Nurs 31:107, 2002
41. Cohen B: Parvovirus B19: An expanding spectrum of disease. BMJ 311:1549, 1995
42. Mayo MA, Martelli GP: Virus taxonomy update. The International Committee on Toxonomy of Viruses. Arch Virol 133:491, 1993
43. Brown KE et al: Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 330:1192, 1994
44. Anand A et al: Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 316:183, 1987
45. Feder HM Jr, Anderson I: Fifth disease. A brief review of infections in childhood, in adulthood, and pregnancy. Arch Intern Med 149:2176, 1989
46. Nocton JJ et al: Human parvovirus B19-associated arthritis in children. J Pediatr 122:186, 1993
47. Lefrere JJ et al: Henoch-Schönlein purpura and human parvovirus infection. Pediatrics 78:183, 1986
48. Woolf AD et al: Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 149:1153, 1989
49. Thurn J: Human parvovirus B19: Historical and clinical review. Rev Infect Dis 10:1005, 1988
50. Faden H, Gary GW Jr, Korman M: Numbness and tingling of fingers associated with parvovirus B19 infection. J Infect Dis 161:354, 1990
51. Harms M, Feldmann R, Saurat JH: Papular-purpuric “gloves and socks” syndrome. J Am Acad Dermatol 23:850, 1990
52. Petter G, Rytter M, Haustein UF: Juvenile papular-purpuric gloves and socks syndrome. J Eur Acad Dermatol Venereol 15:340, 2001
53. Smith PT et al: Papular-purpuric gloves and socks syndrome associated with acute parvovirus B19 infection: Case report and review. Clin Infect Dis 27:164, 1998
54. Grilli R et al: Papular-purpuric “gloves and socks” syndrome: Polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol 41:793, 1999
55. Caul EO, Usher MJ, Burton PA: Intrauterine infection with human parvovirus B19: A light and electron microscopy study. J Med Virol 24:55, 1988
56. Duragon EL et al: Multiple primer pairs for polymerase chain reasction (PCR) amplification of human parvovirus B19 DNA. J Virol Methods 44:155, 1993
57. Young N: Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 25:159, 1988
58. Bertrand Y et al: Autoimmune haemolytic anaemia revealed by human parvovirus linked erythroblastopenia. Lancet 2:382, 1985
59. Ware R: Human parvovirus infection. J Pediatr 114:343, 1989
60. Anderson LJ: Human parvoviruses. J Infect Dis 161:603, 1990
61. Kurtzman G et al: Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 321:519, 1989
62. Levy R et al: Infection by parvovirus B 19 during pregnancy: A review. Obstet Gynecol Surv 52:254, 1997
63. CDC: Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ 300:1166, 1990
64. Mortimer PP et al: Human parvovirus and the fetus. Lancet 2:1012, 1985
65. Weiland HT et al: Parvovirus B19 associated with fetal abnormality. Lancet 1:682, 1987
66. Tiessen RG et al: A fetus with a parvovirus B19 infection and congenital anomalies. Prenat Diagn 14:173, 1994
67.
Silver M: Association of prenatal closure of the foramen ovale and fetal parvovirus B19 infection in hydrops fetalis.
Cardiovasc Pathol 4:103, 1995
68. Garcia-Tapia AM et al: Spectrum of parvovirus B19 infection: Analysis of an outbreak of 43 cases in Cadiz, Spain. Clin Infect Dis 21:1424, 1995
69.
Silver MM et al: Anemia, blueberry-muffin rash, and hepatomegaly in a newborn infant.
J Pediatr 128:579, 1996
70. Finkel TH et al: Chronic parvovirus B19 infection and systemic necrotising vasculitis: Opportunistic infection or aetiological agent? Lancet 343:1255, 1994
71. Corman LC, Dolson DJ: Polyarteritis nodosa and parvovirus B19 infection. Lancet 339:491, 1992
72. Nigro G, Pisano G, Krzysztofiak A: Recurrent Kawasaki disease associated with co-infection with parvovirus B19 and HIV-1. AIDS 7:288, 1993
73. Nesher G, Osborn TG, Moore TL: Parvovirus infection mimicking systemic lupus erythematosus. Semin Arthritis Rheum 24:297, 1995
74. Bansal GP et al: Candidate recombinant vaccine for human B19 parvovirus. J Infect Dis 167:1034, 1993
75. Bell LM et al: Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 321:485, 1989
76. Macsween KF, Crawford DH: Epstein-Barr virus-recent advances. Lancet Infect Dis 3:131, 2003
77. Straus SE et al: NIH conference. Epstein-Barr virus infections: Biology, pathogenesis, and management. Ann Intern Med 118:45, 1993
78. Cohen JI: Epstein-Barr virus infection. N Engl J Med 343:481, 2000
79. Alfieri C et al: Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx. Blood 87:812, 1996
80. Junker AK et al: Epstein-Barr virus shedding in breast milk. Am J Med Sci 302:220, 1991
81. Naher H et al: Subclinical Epstein-Barr virus infection of both the male and female genital tract–indication for sexual transmission. J Invest Dermatol 98:791, 1992
82. Anagnostopoulos I et al: Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: Implications for the interindividual infection route of Epstein-Barr virus. Blood 85:744, 1995
83. Ikediobi NI, Tyring SK: Cutaneous manifestations of Epstein-Barr virus infection. Dermatol Clin 20:283, 2002
84. Sixbey JW et al: Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 310:1225, 1984
85. Junker A.K: Epstein-Barr virus. Pediatr Rev 26:79, 2005
86. Baldari U et al: Skin disorders and Epstein Barr virus primary infection: Results of a 31 month survey. J Eur Acad Dermatol Venereol 4:239, 1995
87. Weary PE, Cole JW III, Hickam LH: Eruptions from
ampicillin in patients with infectious mononucleosis.
Arch Dermatol 101:86, 1970
88. Nazareth I, Mortimer P, McKendrick GD:
Ampicillin sensitivity in infectious mononucleosis–temporary or permanent?
Scand J Infect Dis 4:229, 1972
89. McCarthy JT, Hoagland RJ: Cutaneous Manifestations of Infectious Mononucleosis. JAMA 187:153, 1964
90. Cheng SX et al: Genital ulcers caused by Epstein-Barr virus. J Am Acad Dermatol 51;824, 2004
91. Mendoza N et al: Mucocutaneous manifestations of Epstein-Barr infection. Am J Clin Dermatol 9:295, 2008
92. Barnes CJ et al: Epstein-Barr virus-associated genital ulcers: An underrecognized disorder. Pediatr Dermatol 24:130, 2007
93. Leigh R, Nyirjesy P: Genitourinary manifestations of epstein-barr virus infections. Curr Infect Dis Rep 11:449, 2009
94. Brandt O et al: Gianotti-Crosti syndrome. J Am Acad Dermatol 54:136, 2006
95. Peter J, Ray CG: Infectious mononucleosis. Pediatr Rev 19:276, 1998
96. Ebell MH: Epstein-Barr virus infectious mononucleosis. Am Fam Physician 70:1279, 2004
97. Carter RL: Granulocyte changes in infectious mononucleosis. J Clin Pathol 19:279, 1966
98. Carter RL: Platelet Levels in infectious mononucleosis. Blood 25:817, 1965
99. Finkel M, Parker GW, Fanselau HA: The hepatitis of infectious mononucleosis: Experience with 235 cases. Mil Med 129:533, 1964
100. Auwaerter PG: Infectious mononucleosis in middle age. JAMA 281:454, 1999
101. Hess RD: Routine Epstein-Barr virus diagnostics from the laboratory perspective: Still challenging after 35 years. J Clin Microbiol 42:3381, 2004
102. Linde A: Diagnosis of Epstein-Barr virus-related diseases. Scand J Infect Dis Suppl 100:83, 1996
103. Weedon D: Viral diseases. In: Skin Pathology, edited by D Weedon. London, Churchill Livingstone, 2002 p. 699
104. Farley DR et al: Spontaneous rupture of the spleen due to infectious mononucleosis. Mayo Clin Proc 67:846, 1992
105. Rea TD et al: Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract 14:234, 2001
106. Torre D, Tambini R:
Acyclovir for treatment of infectious mononucleosis: A meta-analysis.
Scand J Infect Dis 31:543, 1999
107. Tynell E et al:
Acyclovir and
prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled study.
J Infect Dis 174:324, 1996
108. Husak R, Garbe C, Orfanos CE: Oral hairy leukoplakia in 71 HIV-seropositive patients: Clinical symptoms, relation to immunologic status, and prognostic significance. J Am Acad Dermatol 35:928, 1996
109. Triantos D et al: Oral hairy leukoplakia: Clinicopathologic features, pathogenesis, diagnosis, and clinical significance. Clin Infect Dis 25:1392, 1997
110. Greenspan JS et al: Replication of Epstein-Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion. N Engl J Med 313:1564, 1985
111. Fernández JF et al: Oral hairy leukoplakia: A histopathologic study of 32 cases. Am J Dermatopathol 12:571, 1990
112. De Souza YG et al: Diagnosis of Epstein-Barr virus infection in hairy leukoplakia by using nucleic acid hybridization and noninvasive techniques. J Clin Microbiol 28:2775, 1990
113. Mabruk MJ et al: In situ hybridization and the polymerase chain reaction (PCR) in the analysis of biopsies and exfoliative cytology specimens for definitive diagnosis of oral hairy leukoplakia (OHL). J Oral Pathol Med 23:302, 1994
114. Landais E, Saulquin X, Houssaint E: The human T cell immune response to Epstein-Barr virus. Int J Dev Biol 49:285, 2005
115. Vokes EE, Liebowitz DN, Weichselbaum RR: Nasopharyngeal carcinoma. Lancet 350:1087, 1997
116. Luk NM et al: Skin metastasis from nasopharyngeal carcinoma in four Chinese patients. Clin Exp Dermatol 29:28, 2004
117. Blum KA, Lozanski G, Byrd JC: Adult Burkitt leukemia and lymphoma. Blood 104:3009, 2004
118. Ferry JA: Burkitt's lymphoma: Clinicopathologic Features and differential diagnosis. Oncologist 11:375, 2006
119. Ohnishi K: Clinicopathological characteristics of Burkitt lymphoma. Nippon Rinsho 58:635, 2000
120. Gandhi MK, Tellam JT, Khanna R: Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol 125:267, 2004
121. Jose BO, Koerner P, Spanos WJ Jr: Hodgkin's lymphoma in adults–clinical features. J Ky Med Assoc 103:15, 2005
122. Rubenstein M, Duvic M: Cutaneous manifestations of Hodgkin's disease. Int J Dermatol 45:251, 2006
123. Su IJ et al: Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma. J Am Acad Dermatol 29:685, 1993
124. Iwatsuki K et al: Clinicopathologic manifestations of Epstein-Barr virus-associated cutaneous lymphoproliferative disorders. Arch Dermatol 133:1081, 1997
125. Yen A et al: EBV-associated Kikuchi's histiocytic necrotizing lymphadenitis with cutaneous manifestations. J Am Acad Dermatol 36:342, 1997
126. Lin HC et al: Kikuchi's disease: A review and analysis of 61 cases. Otolaryngol Head Neck Surg 128:650, 2003
127. Yasukawa K, Matsumura T, Sato-Matsumura KC: Kikuchi's disease and the skin: Case report and review of the literature. Br J Dermatol 144:885, 2001
128. Seno A et al: Kikuchi's disease (histiocytic necrotizing lymphadenitis) with cutaneous involvement. J Am Acad Dermatol 30:504, 1994
129. Taieb A et al: Gianotti-Crosti syndrome: A study of 26 cases. Br J Dermatol 115:49, 1986
130. Brown J, Rentiers R: The Gianotti-Crosti syndrome: A distinctive exanthem. Can Med Assoc J 4:773, 1969
131. Ricci G et al: Gianotti-Crosti syndrome and allergic background. Acta Derm Venereol 83:202, 2003
132. Lee S et al: Gianotti-Crosti syndrome associated with hepatitis B surface antigen (subtype adr). J Am Acad Dermatol 4:629, 1985
133. Hoffman B et al: Gianotti-Crosti syndrome associated with Epstein Barr virus infection. Pediatr Dermatol 14:273, 1997
134. Smith KJ, Skelton H: Histopathologic features seen in Gianotti-Crosti syndrome secondary to EBV. J Am Acad Dermatol 43:1076, 2000
135. Lowe L, Hebert A, Duvic M: Gianotti-Crosti syndrome associated with Epstein-Barr virus infection. J Am Acad Dermatol 20:336, 1989
136. Chuh AA: Diagnostic criteria for Gianotti-Crosti syndrome: A prospective case-control study for validity assessment. Cutis 4:207, 2001
137. Colombo M et al: Immune response to hepatitis B virus in children with papular acrodermatitis. Gastroenterology 4:1103, 1977
138. Chuh A, Lee A, Zawar V: The diagnostic criteria of Gianotti-Crosti syndrome: Are they applicable to children in India? Pediatr Dermatol 4:542, 2004
139. Hjorth N, Kopp H, Osmundsen PE: Gianotti-crosti syndrome—Papular eruption of infancy. Trans St Johns Hosp Dermatol Soc 4:46, 1967
140. Boeck K et al: Gianotti-Crosti syndrome: Clinical, serologic, and therapeutic data from nine children. Cutis 4:271, 1998
141. de Jong MD et al: Summary of the II International Symposium on Cytomegalovirus. Antiviral Res 39:141, 1998
142. Britt W, Alford CA: Cytomegalovirus. In: Fields Virology, edited by B Fields, P Howley. New York, Lippincott-Raven, 1996, p. 2493
143. Boldogh I, Chonmaitree T: Cytomegalovirus. In: Mucocutaneous Manifestations of Viral Diseases, edited by SK Tyring. New York, Marcell Dekker, Inc, 2002, p. 173
144. Gallant JE et al: Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with
zidovudine. The
Zidovudine Epidemiology Study Group.
J Infect Dis 166:1223, 1992
[PubMed: 1358986]
145. Fields BN: Fields Virology, vol 2, 3rd edition, New York, Lippincott-Raven, 1996, p. 2447
146. Hahn G, Jores R, Mocarski ES: Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells.
Proc Natl Acad Sci U S A 95:3937, 1998
[PubMed: 9520471]
147. Grundy JE: Virologic and pathogenetic aspects of cytomegalovirus infection. Rev Infect Dis 12:S711, 1990
148. Riley HD Jr: History of the cytomegalovirus.
South Med J 90:184, 1997
[PubMed: 9042169]
149. Crumpaucer C, Mandell: Douglass and Bennett's Principles and Practice of Infectious Diseases. London, Churchill Livingstone, 2000
150. Boppana SB et al: Symptomatic congenital cytomegalovirus infection: Neonatal morbidity and mortality.
Pediatr Infect Dis J 11:93, 1992
[PubMed: 1311066]
151. Cooper LZ et al: Neonatal thrombocytopenic purpura and other manifestations of rubella contracted in utero.
Am J Dis Child 110:416, 1965
[PubMed: 5890932]
152. Brough AJ et al: Dermal erythropoiesis in neonatal infants. A manifestation of intra-uterine viral disease.
Pediatrics 40:627, 1967
[PubMed: 4293020]
153. Fowler KB, Boppana SB: Congenital cytomegalovirus (
CMV) infection and hearing deficit.
J Clin Virol 35:226, 2006
[PubMed: 16386462]
154. Heilbron B, Saxe N: Scleredema in an infant.
Arch Dermatol 122:1417, 1986
[PubMed: 3789776]
155. Ballard, R.A et al: Acquired cytomegalovirus infection in preterm infants. Am J Dis Child 133:482, 1979
156. Hancox JG et al: Perianal ulcers in an infant: An unusual presentation of postnatal cytomegalovirus infection. J Am Acad Dermatol 54:536, 2006
157. Khoshnevis M, Tyring SK: Cytomegalovirus infections.
Dermatol Clin 20:291, 2002
[PubMed: 12120442]
158. Horwitz CA et al: Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases.
Medicine (Baltimore) 65:124, 1986
[PubMed: 3005799]
159. Kaariainen L, Klemola E, Paloheimo J: Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion. BMJ 5498:1270, 1966
160. Kano Y et al: Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 155:301, 2006
161. Klemola E: Hypersensitivity reactions to
ampicillin in cytomegalovirus mononucleosis.
Scand J Infect Dis 2:29, 1970
[PubMed: 4329122]
162. Spear JB et al: Erythema nodosum associated with acute cytomegalovirus mononucleosis in an adult.
Arch Intern Med 148:323, 1988
[PubMed: 2829764]
163. Asano Y et al: Cytomegalovirus disease during severe drug eruptions: Report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome. Arch Dermatol 145:1030, 2009
164. Bournerias I et al: Unusual cutaneous cytomegalovirus involvement in patients with acquired immunodeficiency syndrome.
Arch Dermatol 125:1243, 1989
[PubMed: 2549883]
165. Portela D et al: OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation.
J Infect Dis 171:1014, 1995
[PubMed: 7706779]
166. Dockrell DH et al: Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease.
J Infect Dis 176:1135, 1997
[PubMed: 9359710]
167. Sissons JG, Carmichael AJ: Clinical aspects and management of cytomegalovirus infection.
J Infect 44:78, 2002
[PubMed: 12076065]
168. Bowden RA et al: A comparison of filtered leukocyte-reduced and cytomegalovirus (
CMV) seronegative blood products for the prevention of transfusion-associated
CMV infection after marrow transplant.
Blood 86:3598, 1995
[PubMed: 7579469]
169. Jacobson MA: Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
N Engl J Med 337:105, 1997
[PubMed: 9211681]
170. Karavellas MP et al: Incidence of immune recovery vitreitis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy.
J Infect Dis 179:697, 1999
[PubMed: 9952380]
171. Meiselman MS, Cello JP, Margaretten W: Cytomegalovirus colitis. Report of the clinical, endoscopic, and pathologic findings in two patients with the acquired immune deficiency syndrome.
Gastroenterology 88:171, 1985
[PubMed: 2981079]
172. Lee JY: Cytomegalovirus infection involving the skin in immunocompromised hosts. A clinicopathologic study.
Am J Clin Pathol 92:96, 1989
[PubMed: 2546421]
173. Feldman PS, Walker AN, Baker R: Cutaneous lesions heralding disseminated cytomegalovirus infection.
J Am Acad Dermatol 7:545, 1982
[PubMed: 6292265]
174. Bhawan J et al: Vesiculobullous lesions caused by cytomegalovirus infection in an immunocompromised adult.
J Am Acad Dermatol 11:743, 1984
[PubMed: 6092440]
175. Lesher JL Jr: Cytomegalovirus infections and the skin.
J Am Acad Dermatol 18:1333, 1988
[PubMed: 2838537]
176. Pariser RJ: Histologically specific skin lesions in disseminated cytomegalovirus infection.
J Am Acad Dermatol 9:937, 1983
[PubMed: 6315790]
177. Warren WP et al: Comparison of rapid methods of detection of cytomegalovirus in saliva with virus isolation in tissue culture.
J Clin Microbiol 30:786, 1992
[PubMed: 1315334]
178. Walker JD, Chesney TM: Cytomegalovirus infection of the skin.
Am J Dermatopathol 4:263, 1982
[PubMed: 6287876]
179. Mattes FM et al: Histopathological detection of owl's eye inclusions is still specific for cytomegalovirus in the era of human herpesviruses 6 and 7.
J Clin Pathol 53:612, 2000
[PubMed: 11002765]
180. Genser B et al: Evaluation of five commercial enzyme immunoassays for the detection of human cytomegalovirus-specific IgM antibodies in the absence of a commercially available gold standard.
Clin Chem Lab Med 39:62, 2001
[PubMed: 11256803]
181. Sandler A, Snedeker JD: Cytomegalovirus infection in an infant presenting with cutaneous vasculitis.
Pediatr Infect Dis J 6:422, 1987
[PubMed: 3035475]
182. Biron KK: Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71:154, 2006
183. Deayton J et al: Loss of cytomegalovirus (
CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy.
AIDS 13:1203, 1999
[PubMed: 10416523]
184. Emery VC: Prophylaxis for
CMV should not now replace pre-emptive therapy in solid organ transplantation.
Rev Med Virol 11:83, 2001
[PubMed: 11262527]
185. Hart GD, Paya CV: Prophylaxis for
CMV should now replace pre-emptive therapy in solid organ transplantation.
Rev Med Virol 11:73, 2001
[PubMed: 11262526]
186. Strippoli GFM et al: Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 1:CD005133, 2006
187. Yamanishi K et al: Identification of human herpesvirus-6 as a causal agent for exanthem subitum.
Lancet 1:1065, 1988
[PubMed: 2896909]
188. Briggs M, Fox J, Tedder RS: Age prevalence of antibody to human herpesvirus 6.
Lancet 1:1058, 1988
[PubMed: 2896904]
189. Okuno T et al: Seroepidemiology of human herpesvirus 6 infection in normal children and adults.
J Clin Microbiol 27:651, 1989
[PubMed: 2542358]
190. Levy JA et al: Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population.
Lancet 335:1047, 1990
[PubMed: 1970369]
191. De Bolle L, Naesens L, De Clercq E: Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 18:217, 2005
192. Brown NA et al: Fall in human herpesvirus 6 seropositivity with age.
Lancet 2:396, 1988
[PubMed: 2899799]
193. Leach CT, Sumaya CV, Brown NA: Human herpesvirus-6: Clinical implications of a recently discovered, ubiquitous agent.
J Pediatr 121:173, 1992
[PubMed: 1322455]
194. Enders G et al: Prevalence of antibodies to human herpesvirus 6 in different age groups, in children with exanthema subitum, other acute exanthematous childhood diseases, Kawasaki syndrome, and acute infections with other herpesviruses and HIV.
Infection 18:12, 1990
[PubMed: 2155875]
195. Tyring S: Mucocutaneous Manifestations of Viral Diseases, edited by S Tyring. New York, Marcell Dekker, 2002
196. Leach CT: Human herpesvirus-6 and -7 infections in children: Agents of roseola and other syndromes.
Curr Opin Pediatr 12:269, 2000
[PubMed: 10836165]
197. Pruksananonda P et al: Primary human herpesvirus 6 infection in young children.
N Engl J Med 326:1445, 1992
[PubMed: 1315416]
198. Schirmer
EC et al: Differentiation between two distinct classes of viruses now classified as human herpesvirus 6.
Proc Natl Acad Sci U S A 88:5922, 1991
[PubMed: 1648234]
199. Wyatt LS, Balachandran N, Frenkel N: Variations in the replication and antigenic properties of human herpesvirus 6 strains.
J Infect Dis 162:852, 1990
[PubMed: 2169499]
200. Dewhurst S et al: Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants. J Clin Microbiol 31:416, 1993
201. Santoro F et al: CD46 is a cellular receptor for human herpesvirus 6.
Cell 99:817, 1999
[PubMed: 10619434]
202. Kempe CH et al: Studies on the etiology of exanthema subitum (roseola infantum).
J Pediatr 37:561, 1950
[PubMed: 14779257]
203. Cone RW et al: Human herpesvirus 6 DNA in peripheral blood cells and saliva from immunocompetent individuals.
J Clin Microbiol 31:1262, 1993
[PubMed: 8388889]
204 Okuno T et al: Human herpesviruses 6 and 7 in cervixes of pregnant women.
J Clin Microbiol 33:1968, 1995
[PubMed: 7665687]
205. Aubin JT et al: Intrauterine transmission of human herpesvirus 6.
Lancet 340:482, 1992
[PubMed: 1354806]
206. Ando Y et al: HHV-6 infection during pregnancy and spontaneous abortion.
Lancet 340:1289, 1992
[PubMed: 1359342]
207. Morris DJ et al: Human herpesvirus 6 infection in renal-transplant recipients.
N Engl J Med 320:1560, 1989
[PubMed: 2542794]
208. Ward KN, Gray JJ, Efstathiou S: Brief report: Primary human herpesvirus 6 infection in a patient following liver transplantation from a seropositive donor.
J Med Virol 28:69, 1989
[PubMed: 2544678]
209. Frenkel N et al: Bone marrow transplant recipients harbor the B variant of human herpesvirus 6.
Bone Marrow Transplant 14:839, 1994
[PubMed: 7889017]
210. Fox JD et al: Human herpesvirus 6 in salivary glands.
Lancet 336:590, 1990
[PubMed: 1697399]
211. Lusso P et al: In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6).
J Exp Med 167:1659, 1988
[PubMed: 3259254]
212. Takahashi K et al: Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus.
J Virol 63:3161, 1989
[PubMed: 2542623]
213. Kondo K et al: Latent human herpesvirus 6 infection of human monocytes/macrophages.
J Gen Virol 72:1401, 1991
[PubMed: 1646280]
214. Luppi M et al: Human herpesvirus 6 latently infects early bone marrow progenitors in vivo.
J Virol 73:754, 1999
[PubMed: 9847383]
215. Kikuta H et al: Frequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from kidney transplant patients.
J Infect Dis 163:925, 1991
[PubMed: 1849169]
216. DesJardin JA et al: Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection.
J Infect Dis 178:1783, 1998
[PubMed: 9815234]
217. Ratnamohan VM et al: Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation.
Transplantation 66:877, 1998
[PubMed: 9798697]
218. Suga S et al: Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child 82:62, 2000
219. Segondy M et al: Herpesvirus 6 infection in young children.
N Engl J Med 327:1099, 1992
[PubMed: 1326080]
220. Singh N, Carrigan DR: Human herpesvirus-6 in transplantation: An emerging pathogen.
Ann Intern Med 124:1065, 1996
[PubMed: 8633821]
221. Asano Y et al: Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum).
Pediatrics 93:104, 1994
[PubMed: 8265302]
222. Yoshikawa T et al: Human herpesvirus-6 infection in bone marrow transplantation.
Blood 78:1381, 1991
[PubMed: 1652312]
223. Yoshikawa T et al: Human herpesvirus 6 viremia in bone marrow transplant recipients: Clinical features and risk factors.
J Infect Dis 185:847, 2002
[PubMed: 11920307]
224. Levine PH et al: Detection of human herpesvirus 6 in tissues involved by sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease).
J Infect Dis 166:291, 1992
[PubMed: 1321861]
225. Luppi M et al: Expression of human herpesvirus-6 antigens in benign and malignant lymphoproliferative diseases.
Am J Pathol 153:815, 1998
[PubMed: 9736030]
226. Hall CB et al: Human herpesvirus-6 infection in children. A prospective study of complications and reactivation.
N Engl J Med 331:432, 1994
[PubMed: 8035839]
227. Suga S et al: IgM neutralizing antibody responses to human herpesvirus-6 in patients with exanthem subitum or organ transplantation.
Microbiol Immunol 36:495, 1992
[PubMed: 1325026]
228. Bland RM et al: The rapid diagnosis and clinical features of human herpesvirus 6.
J Infect 36:161, 1998
[PubMed: 9570647]
229. Tanaka H et al: Human herpesvirus 6-associated hemophagocytic syndrome in a healthy adult.
Emerg Infect Dis 8:87, 2002
[PubMed: 11749757]
230. Cone RW et al: Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation.
N Engl J Med 329:156, 1993
[PubMed: 8390614]
231. Carrigan DR et al: Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation.
Lancet 338:147, 1991
[PubMed: 1677066]
232. Drobyski WR et al: Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: Evidence of a marrow-suppressive role for HHV-6 in vivo.
J Infect Dis 167:735, 1993
[PubMed: 8382723]
233. Carrigan DR, Knox KK: Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients.
Blood 84:3307, 1994
[PubMed: 7949085]
234. Zhang Y, Schols D, De Clercq E: Selective activity of various antiviral compounds against HHV-7 infection.
Antiviral Res 43:23, 1999
[PubMed: 10480261]
235. Yoshida M et al: Comparison of antiviral compounds against human herpesvirus 6 and 7.
Antiviral Res 40:73, 1998
[PubMed: 9864048]
236. Rapaport D et al: Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients.
Transpl Infect Dis 4:10, 2002
[PubMed: 12123421]
237. Hidaka Y et al: Exanthem subitum and human herpesvirus 7 infection.
Pediatr Infect Dis J 13:1010, 1994
[PubMed: 7845722]
238. Wyatt LS et al: Human herpesvirus 7: Antigenic properties and prevalence in children and adults.
J Virol 65:6260, 1991
[PubMed: 1656093]
239. Hall CB et al: Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6.
J Infect Dis 193:1063, 2006
[PubMed: 16544246]
240. Wyatt LS, Frenkel N: Human herpesvirus 7 is a constitutive inhabitant of adult human saliva.
J Virol 66:3206, 1992
[PubMed: 1348548]
241. Frenkel N et al: Isolation of a new herpesvirus from human CD4
+ T cells.
Proc Natl Acad Sci U S A 87:748, 1990
[PubMed: 2153965]
242. Lusso P et al: CD4 is a critical component of the receptor for human herpesvirus 7: Interference with human immunodeficiency virus.
Proc Natl Acad Sci U S A 91:3872, 1994
[PubMed: 7909607]
243. Black JB, Pellett PE: Human herpesvirus 7.
Rev Med Virol 9:245, 1999
[PubMed: 10578120]
244. Katsafanas GC et al: In vitro activation of human herpesviruses 6 and 7 from latency.
Proc Natl Acad Sci U S A 93:9788, 1996
[PubMed: 8790409]
245. Tortorella D et al: Viral subversion of the immune system.
Annu Rev Immunol 18:861, 2000
[PubMed: 10837078]
246. Lorenzo ME, Ploegh HL, Tirabassi RS: Viral immune evasion strategies and the underlying cell biology.
Semin Immunol 13:1, 2001
[PubMed: 11330438]
247. Furukawa M et al: Distinct effects of human herpesvirus 6 and human herpesvirus 7 on surface molecule expression and function of CD4
+ T cells.
J Immunol 152:5768, 1994
[PubMed: 7911490]
248. Hudson AW, Howley PM, Ploegh HL: A human herpesvirus 7 glycoprotein, U21, diverts major histocompatibility complex class I molecules to lysosomes.
J Virol 75:12347, 2001
[PubMed: 11711625]
249. Tanaka K et al: Human herpesvirus 7: Another causal agent for roseola (exanthem subitum).
J Pediatr 125:1, 1994
[PubMed: 8021757]
250. Drago F et al: Human herpesvirus 7 in pityriasis rosea.
Lancet 349:1367, 1997
[PubMed: 9149704]
251. Karabulut AA et al: Detection of human herpesvirus 7 in pityriasis rosea by nested PCR.
Int J Dermatol 41:563, 2002
[PubMed: 12358824]
252. Kempf W et al: Pityriasis rosea is not associated with human herpesvirus 7.
Arch Dermatol 135:1070, 1999
[PubMed: 10490111]
253. Kosuge H et al: Epidemiological study of human herpesvirus-6 and human herpesvirus-7 in pityriasis rosea. Br J Dermatol 143:795, 2002
254. Drago F et al: J Am Acad Dermatol 61:303, 2009
255. DeVries HJ et al: Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cells. Br J Dermatol 154:361, 2006
256. Caserta MT et al: Primary human herpesvirus 7 infection: A comparison of human herpesvirus 7 and human 6 infections in children.
J Pediatr 133:386, 1998
[PubMed: 9738722]
257. Huang LM et al: Primary infections of human herpesvirus-7 and herpesvirus-6: A comparative, longitudinal study up to 6 years of age.
Acta Paediatr 86:604, 1997
[PubMed: 9202795]
258. Drobyski WR et al: Brief report: Fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow-transplant recipient. N Engl J Med 330:1356, 1992
259. Torigoe S et al: Human herpesvirus 7 infection associated with central nervous system manifestations.
J Pediatr 129:301, 1996
[PubMed: 8765632]
260. Stalkup JR, Chilukuri S: Enterovirus infections: A review of clinical presentation, diagnosis, and treatment.
Dermatol Clin 20:217, 2002
[PubMed: 12120436]
261. Sawyer MH: Enterovirus infections: Diagnosis and treatment.
Pediatr Infect Dis J 18:1033, 1999
[PubMed: 10608620]
262. Shimizu H et al: Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997–1998. Jpn J Infect Dis 5:12, 1999
263. Shimizu H, Okuyama K, Hirai Y: Epidemic of hand, foot and mouth disease in Kawasaki City, Japan. Jpn J Infect Dis 1:330, 2005
264. Shekhar K et al: Deaths in children during an outbreak of hand, foot and mouth disease in Peninsular Malaysia—clinical and pathological characteristics. Med J Malaysia 4:297, 2005
265. Ferson MJ, Bell SM: Outbreak of coxsackievirus A16 hand, foot, and mouth disease in a child day-care center. Am J Public Health 6:1675, 1991
266. Chang LY et al: Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 6:1092, 1999
267. Chan LG et al: Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: Clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 3:678, 2000
268. Chan KP et al: Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 4:78, 2003
269. Ho M et al: An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 4:929, 1999
270. Chang LY et al: Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan. JAMA 7:222, 2004
271. Adler JL et al: Epidemiologic investigation of hand, foot, and mouth disease. Infection caused by coxsackievirus A 16 in Baltimore, June through September 1968. Am J Dis Child 4:309, 1970
272. Froeschle JE et al: Hand, foot, and mouth disease (Coxsackievirus A16) in Atlanta. Am J Dis Child 4:278, 1967
273. Ho M et al: An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group.
N Engl J Med 341:929, 1999
[PubMed: 10498487]
274. Fields JP et al: Hand, foot, and mouth disease. Arch Dermatol 6:243, 1969
275. Wang SM et al: Therapeutic efficacy of
milrinone in the management of enterovirus 71-induced pulmonary edema.
Pediatri Pulmonol 39:219, 2005
276. Xiuling L et al: Generation of neutralizing monoclonal antibodies against enteorvirus 72 using synthetic peptides. Bio Chem Bio Phys Comm 390:1126, 2009.
277. Chang LY et al: Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 4:e88, 2002
278. Galen W: Cutaneous manifestations of enterovirus infections. In: Mucocutaneous Manifestations of Viral Diseases, edited by SK Tyring. New York, Marcel-Dekker, Inc., 455, 2002
279. Cramblett HG, Parrott RH: Nonbacterial infections affecting the nasopharynx. Pediatr Clin North Am 4:115, 1957
280. Hosoya M et al: Diagnosis of group A coxsackieviral infection using polymerase chain reaction. Arch Dis Child 9:316, 2002
281. Cherry JD et al: Acute hemangioma-like lesions associated with ECHOviral infections. Pediatrics 44:498, 1969
282. Angelo C et al: Eruptive pseudoangiomatosis. Pediatr Dermatol 19:243, 2002.
283. Guillot B, Dandurand M: Eruptive pseudoangiomatosis arising in adulthood: 9 cases. Eur J Dermatol 10:455, 2000
284. Venturi C et al: Eruptive pseudoangiomatosis in adults: A community outbreak. Arch Dermatol 140:757, 2004
285. Morens DM: Boston exanthem agent: Echovirus 16. Am J Dis Child 131:1306, 1977
286. James WD et al: Viral disease. In: Andrews' Diseases of the Skin: Clinical Dermatology, edited by William D James, Timothy G Berger, Dirk MD Elston. Saint Louis, MO, Saunders Elsevier, 2006, p. 399
287. Musher DM, Musher BL: Contagious acute gastrointestinal infections.
N Engl J Med 351:2417, 2004
[PubMed: 15575058]
288. Glass RI et al: The epidemiology of rotavirus diarrhea in the United States: Surveillance and estimates of disease burden. J Infect Dis 174:S5, 1996
289. Dennehy PH: Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J 19:S103, 2000
290. Champsaur H et al: Rotavirus carriage, asymptomatic infection, and disease in the first two years of life. I. Virus shedding.
J Infect Dis 149:667, 1984
[PubMed: 6327844]
291. Bellamy K et al: A test for the assessment of “hygienic” hand disinfection using rotavirus.
J Hosp Infect 24:201, 1993
[PubMed: 8104210]
292. McCormack JG: Clinical features of rotavirus gastroenteritis.
J Infect 4:167, 1982
[PubMed: 7185988]
293. Rodriguez WJ et al: Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: Clinical and epidemiologic observations.
Pediatr Infect Dis J 6:170, 1987
[PubMed: 3031575]
294. Estes MK, Cohen J: Rotavirus gene structure and function.
Microbiol Rev 53:410, 1989
[PubMed: 2556635]
295. Blutt SE et al: Rotavirus antigenaemia and viraemia: A common event?
Lancet 362:1445, 2003
[PubMed: 14602437]
296. Huang XL et al: [Viraemia and extraintestinal involvement after rotavirus infection].
Zhejiang Da Xue Xue Bao Yi Xue Ban 35:69, 2006
[PubMed: 16470924]
297. Gurwith M et al: A prospective study of rotavirus infection in infants and young children.
J Infect Dis 144:218, 1981
[PubMed: 6268713]
298. Staat MA et al: Clinical presentations of rotavirus infection among hospitalized children.
Pediatr Infect Dis J 21:221, 2002
[PubMed: 12005086]
299. Ruzicka T, Rosendahl C, Braun-Falco O: A probable case of rotavirus exanthem.
Arch Dermatol 121:253, 1985
[PubMed: 3977344]
300. Dilernia V, Ricci, C. Skin manifestations with rotavirus infections. Int. J Dermatol 46:759: 2006
301. Patrizi A et al: Exanthem in children with rotavirus infection. J Eur Acad Dermatol Venereol 8:145, 1997
302. Annalisa P et al: Papular or papulovesicular syndromes.
Arch Dermatol 124:1444, 1988
[PubMed: 3046502]
303. Di Lernia V: Gianotti-Crosti syndrome related to rotavirus infection.